Neuroendocrine Tumors

Well Differentiated

1st Line

Operable

NET0030
Pilot Phase 1 Study of Perioperative Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic, WHO Grade 1 or 2, SSTR Positive, Gastroenteropancreatic Neuroendocrine Tumors

P: Visser Pending 1st Priority

Inoperable

NET0028
Phase III 177Lu-Edototide vs Targeted MolecularTherapy w/ Everolimus in SSTR+ Neuroendocrine Tumours

P: Aparici Sponsor: ITM GmbH 1st Priority

2nd Line

ECOG-ACRIN A021602
Phase III Cabozantinib vs Placebo in Advanced Neuroendocrine Tumors After Progression on Everolimus

P: Shahguda ECOG-ACRIN

1st Priority

KEY

Pending
Open for Enrollment
Observational Study
Optional Path
Link
Trial Posting
Extension Study
Immunotherapy
Enrollment on Hold